Allgemein

Der Bundesrechnungshof hat scharfe Kritik an der Maskenbeschaffung in der Coronakrise unter Bundesgesundheitsminister Jens Spahn (CDU) geübt und dessen Haus eine mangelnde Aufarbeitung vorgeworfen. „Die massive Überbeschaffung von Schutzmasken zu Beginn der Coronapandemie durch das Bundesministerium für Gesundheit (BMG) führte zu anhaltend hohen Lagerbeständen und erheblichen Folgekosten“, heißt es in einem Bericht des Bundesrechnungshofs an…

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. Junshi Biosciences Announces 2023 Full Year Financial…

Record consolidated net revenue of $84.5 million for full-year 2023 Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Hautnah am Zeitgeist, an den wichtigen Themen des politischen Weltgeschehens, interessiert an den Geschichten seiner erdachten, aber realen Protagonisten – das ist das musikalische Triptychon, das Fischer-Z schon seit jeher ausmachen, und das auch wieder auf dem neuen Album „Triptych“ und im Frühjahr 2024 live auf der Bühne präsentiert wird. Die Band, im Vergleich zur…

CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva…

Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024. Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

CHAPEL HILL, N.C., March 28, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced full year 2023 financial results, and provided clinical development and business updates. Tenax Therapeutics Provides Business…